Abstract
Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) is predictive for post-operative recurrence in lung cancer. However, the suitable approach for sensible MRD monitoring remains controversial. Currently, whole-exome sequencing (WES) is widely used to design the customized monitoring panels of tumor-informed assay for MRD monitoring. We investigated the potential factors which may affect the performance of whole-exome sequencing (WES) for monitoring panels’ design.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
